2013 Viral Clearance Symposia - Session 5. Conference Summary: Key Discussion and
Outcomes, Pending Questions, and Proposed Experiments | PDA Journal of Pharmaceutical …

Viral clearance and inactivation by the bulk protein purification process are a critical
component of the overall strategy to ensure the safety of therapeutic proteins derived from …

Viral Clearance Symposium 2017 Conclusion | PDA Journal of Pharmaceutical Science and
Technology Skip to main content Main menu Home Content Current Issue Past Issues …

The 2023 Viral Clearance Symposium (VCS) was hosted by Takeda on 24 and 25 May 2023
in Vienna, Austria. The present conference extended the structure of the previous biennial …

The 2009 Viral Clearance Symposium (Indianapolis, IN, USA) was held to interactively
discuss methods for virus removal and inactivation during biopharmaceutical manufacture …

Adventitious contamination of a manufacturing process is a major concern for
biopharmaceutical manufacturers. This session focused on rapid detection methods for …

Viral clearance (VC) studies are mandatory for biologic drugs, which are pharmaceutically
derived from human and/or animal sources such as cell line-derived recombinant proteins …

This article introduces the white paper from the 2017 Viral Clearance Symposium. The 5th
Viral Clearance Symposium in Penzberg, Germany, addressed regulatory perspectives …

This report provides a high-level summary of the key outcomes and gaps based on the
research presented at the Viral Clearance Symposium 2017 and identifies new areas for …

Viral clearance (VC) studies are mandatory for biologic drugs, which are pharmaceutically
derived from human and/or animal sources such as cell line-derived recombinant proteins …